Preferred Label : futibatinib;

UNII : 4B93MGE4AL;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.has-sante.fr/jcms/p_3490351/fr/lytgobi-futibatinib-cholangiocarcinome
2024
false
false
false
France
futibatinib
treatment outcome
insurance, health, reimbursement
adult
Intrahepatic Cholangiocarcinoma
antineoplastic agents
Locally Advanced Intrahepatic Cholangiocarcinoma
Metastatic Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
FGFR2 Gene Rearrangement
FGFR2 Gene Fusion Positive
Cancer Progression
administration, oral
evaluation of the transparency committee
cholangiocarcinoma
futibatinib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
futibatinib
futibatinib
futibatinib
drug approval
europe
receptor, fibroblast growth factor, type 2
FGFR2 Positive
cholangiocarcinoma
neoplasm metastasis
Metastatic Cholangiocarcinoma
Unresectable Cholangiocarcinoma
Refractory Cholangiocarcinoma
adult
administration, oral
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
antineoplastic agents
antineoplastic agents
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
Female of Childbearing Potential
receptors, fibroblast growth factor
drug evaluation, preclinical

---
Nous contacter.
25/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.